

FINANCIAL TEAR SHEET

Corporate Profile

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair and CEO Christoph Westphal, M.D., Ph.D.

Primary IR Contact


E-mail: irdept@flex-pharma.com

Stock Performance

FLKS (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$4.57
Change (%)	▲ 0.12 (2.70%)
Volume	1,049,092
52 Week Low	\$3.01
Market Cap	\$79,969,126
Rolling EPS	-2.32
PE Ratio	0
Shares Outstanding	17,970,590

Data as of 06/23/17 4:00 p.m. ET



Symbol
FLKS (Common Stock)

Time Frame

Frequency

Chart Type

Recent Headlines & Events

06/05/17 - 4:10 p.m.

[Flex Pharma Announces Executive Leadership Transition](#)

There are currently no events scheduled.

06/02/17 - 8:01 a.m.

[Flex Pharma's Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium](#)

05/30/17 - 9:24 a.m.

[Flex Pharma Presenting at Upcoming Investor Conferences in June 2017](#)

SEC Filings

Filing Date	Form
06/06/17	8-K
05/30/17	4
05/03/17	10-Q
05/03/17	8-K

Fundamentals, Copyright Thomson Reuters Corporation

Data Provided by Thomson Reuters

Minimum 20 minutes delayed